Literature DB >> 20812149

Small-molecule PARP modulators--current status and future therapeutic potential.

Thomas D Penning1.   

Abstract

PARP-1 inhibitors have emerged as a promising therapeutic class of compounds, and numerous PARP inhibitors, including iniparib (BiPar Sciences Inc/sanofi-aventis), olaparib (AstraZeneca plc), veliparib (Abbott Laboratories), PF-1367338 (Pfizer Inc), MK-4827 (Merck & Co Inc) and CEP-9722 (Cephalon Inc), have advanced into clinical trials. Several additional inhibitors are expected to enter clinical trials within the next year. Early investigations with PARP-1 inhibitors involved non-oncological indications, but development has since progressed to focus primarily on oncology, for use both as single chemotherapeutic agents in specific patient populations (eg, BRCA-deficient) and as combination therapies with various chemotherapeutics. This review focuses on new developments in lead clinical PARP inhibitors, recent disclosures of new inhibitors and the potential use of PARP-1 inhibitors in new disease settings.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20812149

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN： 1367-6733


  13 in total

1.  Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Authors:  Anand G Patel; Silvana B De Lorenzo; Karen S Flatten; Guy G Poirier; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-01-30       Impact factor: 12.531

2.  Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies.

Authors:  Shailly Mehrotra; Mathangi Gopalakrishnan; Jogarao Gobburu; Jacqueline M Greer; Richard Piekarz; Judith E Karp; Keith Pratz; Michelle A Rudek
Journal:  Br J Clin Pharmacol       Date:  2017-03-19       Impact factor: 4.335

Review 3.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

4.  Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice.

Authors:  Viktor R Drel; Pal Pacher; Roman Stavniichuk; Weizheng Xu; Jie Zhang; Tamara M Kuchmerovska; Barbara Slusher; Irina G Obrosova
Journal:  Int J Mol Med       Date:  2011-05-23       Impact factor: 4.101

5.  MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.

Authors:  Li Wang; Kathy A Mason; K Kian Ang; Thomas Buchholz; David Valdecanas; Anjili Mathur; Carolyn Buser-Doepner; Carlo Toniatti; Luka Milas
Journal:  Invest New Drugs       Date:  2011-11-30       Impact factor: 3.850

Review 6.  PARP Inhibitors in Prostate Cancer.

Authors:  Praveen Ramakrishnan Geethakumari; Matthew J Schiewer; Karen E Knudsen; Wm Kevin Kelly
Journal:  Curr Treat Options Oncol       Date:  2017-06

Review 7.  Selective tumor killing based on specific DNA-damage response deficiencies.

Authors:  Michael Biss; Wei Xiao
Journal:  Cancer Biol Ther       Date:  2012-03-01       Impact factor: 4.742

Review 8.  PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis.

Authors:  Marie-France Langelier; John M Pascal
Journal:  Curr Opin Struct Biol       Date:  2013-01-16       Impact factor: 6.809

9.  PARP1 is required for chromosomal translocations.

Authors:  Justin Wray; Elizabeth A Williamson; Sudha B Singh; Yuehan Wu; Christopher R Cogle; David M Weinstock; Yu Zhang; Suk-Hee Lee; Daohong Zhou; Lijian Shao; Martin Hauer-Jensen; Rupak Pathak; Virginia Klimek; Jac A Nickoloff; Robert Hromas
Journal:  Blood       Date:  2013-04-08       Impact factor: 22.113

10.  C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.

Authors:  Jiahong Tan; Xu Zheng; Mengchen Li; Fei Ye; Chunyan Song; Cheng Xu; Xiaoxue Zhang; Wenqian Li; Ya Wang; Shaoqing Zeng; Huayi Li; Gang Chen; Xiaoyuan Huang; Ding Ma; Dan Liu; Qinglei Gao
Journal:  Oncogene       Date:  2021-05-08       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.